Recent Trends in Aspirin Use for Primary and Secondary Cardiovascular Disease Prevention in the United States - 2015-2021

Karthik Murugiah MD[1,2]; Claudia See, BS[3]

[1]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

[2]Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT

[3]Yale School of Medicine, New Haven, CT

Correspondence: Karthik Murugiah MD, 195 Church St, 6th Floor, New Haven, CT 06510; 203-487-1239 (tel). 203-764-5653 (fax).

Key words: Aspirin, primary prevention, secondary prevention, trends

Abstract Word Count: 175

Manuscript Word Count: 1077

ABSTRACT

Background:

Recent trials show a lack of benefit of routine aspirin use for primary prevention and potential for harm. We assessed recent trends in aspirin use for both primary and secondary prevention in the United States population

Methods:

We used National Health Interview Survey (NHIS) data from 2015-2021 and reported the annual weighted proportion of aspirin use among patients ≥40 years without a self-reported history of angina, coronary heart disease, myocardial infarction, or stroke (primary prevention cohort) and those with (secondary prevention cohort) overall and by subgroups of sex, age ≥70 years and diabetes status.

Results:

The proportion of patients on aspirin for primary prevention reduced from 24.8% in 2015 to 13.9% in 2021 and secondary prevention reduced from 67.6% to 45.9%. The reduction in aspirin use was observed across all subgroups and in both cohorts.

Conclusion:

In response to recent data regarding lack of benefit of aspirin for primary prevention there has been a significant reduction in aspirin use for both primary and secondary prevention, the latter may be unintended and warrants further scrutiny.

INTRODUCTION:

Aspirin has been long used to reduce cardiovascular events among individuals at increased atherosclerotic cardiovascular disease (ASCVD) risk. However, recent data from large randomized trials published in 2018(1-3) have called into question the routine use of aspirin for primary prevention and potential for harm in older adults. In response to these data in March 2019 the American Heart Association and American College of Cardiology (AHA/ACC) updated their guidelines, and made a recommendation against routine aspirin use in persons older than 70 years and those with increased bleeding risk (4). The United States Preventive Services Task Force (USPTF) has also since updated their guidelines with an even more stringent recommendation against initiation of low-dose aspirin use for primary prevention in adults >/=60 years (5).

The change in recommendations for aspirin is one of the most major guideline changes in recent times and represents a paradigm shift in cardiovascular prevention. However, it is unknown whether in response to these data and guideline changes there has been a reduction in aspirin use for primary prevention generally or in certain sub-groups of patients. Further, with the significant media attention that the recent aspirin for primary prevention trials has garnered, has there been an unintended decline in aspirin use for secondary prevention.

To study the recent trends in aspirin use in the population of the United States (US), we used data from the nationally representative National Health Interview Survey

(NHIS) from 2015-2021. The NHIS is the principal source of information on the health of the civilian noninstitutionalized US population (6).

METHODS:

Data Source:

We used data from the NHIS Sample Adult file from 2015-2021. The content and structure of the NHIS were updated in 2019. The NHIS introduced the rotating core part of the questionnaire which consists of questions that are included in the interview on some years with fixed periodicity. The questions regarding aspirin use were changed to a biennial schedule and were collected in 2019 and 2021 and not in 2020. The redesign does not affect the questions regarding cardiovascular risk factors and established CVD which have remained the same. We reported aspirin use for 2015-2019 and 2021.
In 2019 the NHIS redesign adopted a new weighting approach to address non-respondent bias. This survey redesign affects comparisons between 2019 to earlier years.

Study population:

The primary prevention cohort included all participants over the age of 40 without a self-reported history of angina, coronary heart disease, myocardial infarction, or stroke. The secondary prevention cohort included all participants who reported a history of angina, coronary heart disease, myocardial infarction, or stroke. Cardiovascular risk factors and established cardiovascular disease were identified by the specific survey questions as following - 1) Ever been told you had angina pectoris. 2) Ever been told

you had coronary heart disease 3) Ever been told you had a heart attack. 4) Ever been told you had a stroke. The NHIS interview contains the following questions regarding aspirin use – 1) Has a doctor or other health professional ever told you to take a low-dose aspirin each day to prevent or control heart disease? 2) Are you now following this advice? 3) Did a doctor or other health professional advise you to stop taking a low-dose aspirin every day? 4) On your own, are you now taking a low-dose aspirin each day to prevent or control heart disease? We classified participants who answered “yes” to either question 2 or 4 as taking aspirin.

Statistical analysis:

Weighted proportion of patients on aspirin was reported. Weighting methodology incorporated the NHIS strata, primary sampling unit, and sample adult weights to produce nationally representative estimates using the svy set of commands for structured survey data. Aspirin use in subgroups between 2015 and 2021 were compared using Chi Squared tests. Given the public nature of NHIS data this study was exempt from individual patient consent. Data analysis was conducted using Stata version 17, College Station, TX.

RESULTS:

The proportion of patients ≥ 40 years on aspirin regardless of indication was similar during the period 2015 (30%) to 2019 (26.3%) and then a significant reduction was noted in 2021 (17.9%) (P value 2021 vs 2015 <0.001).

The reduction in aspirin use was noted in both the primary and secondary prevention cohorts and across all sub groups (Table 1). Reduction in aspirin use was also noted in cohorts that may stand to benefit most from aspirin such as patients <70 years of age but with both diabetes and established cardiovascular disease (CVD) (75.7% in 2015 vs 49.7% in 2021). All P <0.001.

DISCUSSION:

Our study shows the immediate impact of the recent trial data regarding aspirin and guideline changes on aspirin use in a nationally representative sample of the US population. In response, aspirin use declined in populations that do not stand to benefit such as patients older than 70 years and without established CVD. However, we also observed a decrease in aspirin use in populations with established CVD which is an unintended effect and cause for alarm. It is possible that some of this reduction may be due to physicians increasingly using single P2Y12 inhibitor therapy after PCI etc. as well as avoiding additional aspirin on patients on chronic anticoagulation for secondary prevention, but the degree of reduction in aspirin use is beyond what can be expected from these practice changes.

Study Limitations: Our study has limitations that warrant consideration. First, the NHIS database provides self-reported patient survey data that may be subject to selection biases such as non-response bias or observation biases such as reporting bias. Second, data on aspirin use was only available on adults ≥40 years. Data on other antiplatelet and anticoagulant agents as well as bleeding diathesis were not available.

Also, this analysis looks only at patients taking aspirin, and does not examine whether patients may be concurrently prescribed other medications for CVD. Third, aspirin data was not collected in 2020. Finally, the NHIS redesign of 2019 affects comparisons of 2019 to earlier years. However, this does not affect comparison of estimates between 2019 and 2021 which is the period where a significant decline in aspirin use was noted.

CONCLUSION:

Recent data regarding lack of benefit of aspirin for primary prevention have led to reductions in aspirin use for primary prevention. However, there has been a reduction in aspirin use among patients for secondary prevention which warrants scrutiny. There is a need for the medical and cardiology community to ensure that their patients are appropriately informed and on appropriate prevention regimens.

REFERENCES:

1. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine 2018;379:1529-1539.
2. Gaziano JM, Brotons C, Coppolecchia R et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet 2018;392:1036-1046.
3. McNeil JJ, Nelson MR, Woods RL et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine 2018;379:1519-1528.
4. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-e646.
5. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication. 2022.
6. Centers for Disease Control and Prevention. About the National Health Interview Survey. Reviewed March 3, 2022. Accessed August 21, 2022.

Table 1: Weighted Proportion of Patients ≥40 years on Aspirin for Primary and Secondary Prevention, Overall and by Subgroups

Weighted proportion (%)	Primary prevention					
	2015	2016	2017	2018	2019*	2021
N	19271	19170	15594	15075	19178	17972
Weighted N	131,782,058	132,374,824	132,793,894	135,255,327	135,762,808	138,946,133
Overall	24.8	24.5	24.9	23.2	20.5	13.9
Male	26.8	26.6	27.0	25.7	22.4	14.9
Female	23.1	22.7	23.2	21.2	18.9	13.0
Age≥70	45.1	45.6	46.6	44.9	37.9	25.8
Age<70	20.6	20.2	20.1	18.4	16.3	10.7
Diabetes	48.9	47.8	47.4	45.7	43.7	28.7
No diabetes	21.5	21.5	22.0	20.2	17.5	11.8
	Secondary prevention					
N	3057	3201	2579	2585	3167	2914
Weighted N	18,089,497	18,997,188	19,737,572	19,800,648	19,946,342	20,085,724
Overall	67.6	67.9	66.9	66.3	65.6	45.9
Male	71.2	73.4	72.5	70.4	70.9	49.4
Female	63.2	61.1	59.0	60.7	59.0	41.4
Age≥70	68.0	70.7	69.8	67.9	66.2	48.4
Age<70	67.3	65.5	64.4	64.8	65.1	43.5
Diabetes	75.1	72.8	70.2	74.2	71.9	51.0
No diabetes	63.9	65.8	65.5	62.4	62.9	43.8

All P for comparison 2021 vs 2015 <0.001
* Survey redesign in 2019 affects comparisons between 2019 to earlier years.